Should a booster dose be administered in children after mass immunization for hepatitis B?

Simple item page
dc.contributor.authorTosun S.
dc.contributor.authorDeveci S.
dc.contributor.authorKaplan Y.
dc.contributor.authorKasirga E.
dc.date.accessioned2024-07-22T08:20:31Z
dc.date.available2024-07-22T08:20:31Z
dc.date.issued2011
dc.description.abstractBackground: Hepatitis B virus infection is a global health problem and vaccine-preventable disease, but the duration of the effects of HBV vaccination in infants is unknown. Objectives: The aim of this trial, which comprised children who had received 3 doses as part of the universal HBV immunization program and no additional doses, was to investigate anti-HBs titers and HBsAg status after 9 years. Patients and Methods: We performed a descriptive, cross-sectional field research study. The study sample, based on sociodemographics and minimum seroprevalence, was analyzed based on 10.00% ± 1.50 (95% confidence interval) (1150 individuals); trial was realized in a total of 1279 children (623 females and 656 males). Anti-HBs titers were measured by micro-EIA (Dia Sorin-Italy); titers < 10 IU/mL were negative, 10-49 IU/mL were low-positive, and > 50 IU/mL were high-positive. For anti-HBs titers below protective levels, HBsAg was measured by micro-EIA. Results: In approximately half of the children (48.5% in those living in semiurban areas and 42.3% in urban areas), antibody titers were below protective levels. Conclusions: Mass HBV vaccination, which was implemented in Turkey in 1998, significantly decreases HBsAg positivity in childhood. Nevertheless, it might be necessary to administer a booster dose after 8-9 years in children, especially those in low socioeconomic areas or in whom irregular/insufficient immunization is suspected. © 2011 Kowsar M.P.Co. All rights reserved.
dc.identifier.issn1735143X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18179
dc.language.isoEnglish
dc.publisherBrieflands
dc.subjecthepatitis B surface antibody
dc.subjecthepatitis B surface antigen
dc.subjecthepatitis B vaccine
dc.subjectantibody titer
dc.subjectarticle
dc.subjectchild
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectdemography
dc.subjectdescriptive research
dc.subjectfemale
dc.subjectfield study
dc.subjecthepatitis B
dc.subjecthuman
dc.subjectimmunocompetence
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmass immunization
dc.subjectoutcome assessment
dc.subjectseroprevalence
dc.subjectsocial status
dc.subjectTurkey (republic)
dc.subjecturban area
dc.titleShould a booster dose be administered in children after mass immunization for hepatitis B?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu